The HepQuant CLIA-certified laboratory tests serum samples from clinical trials with pharmaceutical companies and academic researcher centers. To date, we have provided the HepQuant SHUNT test pursuant to the FDA’s Investigational Device Exemption (IDE) regulation. Visit the Resources Page to read peer-reviewed papers and scientific posters.
Coming soon, the HepQuant DuO Test, our LDT, will be offered for use in clinical trials. Unlike the HepQuant SHUNT Test, the HepQuant DuO Test does not require injections of cholate and requires only two blood draws instead of five.
Non-invasive, true functional liver tests
Our tests measure hepatic blood flow, portal blood flow, and portal-systemic shunt in patients with chronic liver disease. The tests are designed to evaluate all levels of hepatic impairment, regardless of the etiology of the liver disease. HepQuant provides quantitative liver function tests as a service to liver research centers and pharmaceutical companies.
Our services include:
- Consultative Services – Analysis and assessments of research applications of HepQuant tests
- Lab Services – Processing and analysis of serum samples
- Modeling and Reporting Services – Analysis of data and relationship to utility and outcomes
Need More Information?
Add HepQuant DuO to your clinical trial
HepQuant DuO is a Laboratory Developed Test (LDT). This test was developed and its performance characteristics determined by HepQuant, LLC in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.
The HepQuant DuO Test is not available for sale. It will be available soon to healthcare professionals as an adjunctive aid in assessment of liver function, in conjunction with clinical evaluation and other tests.